1. Neurocrine Biosciences, Inc.
  2. Neurocrine Biosciences, Inc. Ownership

Historical shareholding details of Lazard Asset Management LLC holdings in Neurocrine Biosciences, Inc. (NBIX)

Monthly changes of Lazard Asset Management LLC shareholding in Neurocrine Biosciences, Inc. over the previous months

Month Name Total no. shares held Percent Holding
Feb 28, 2025 Lazard Asset Management Llc 18,580 0.02%
Jan 31, 2025 Lazard Asset Management Llc 18,645 0.02%
Dec 31, 2024 Lazard Asset Management Llc 59,279 0.06%
Dec 31, 2024 Lazard Asset Management Llc 18,645 0.02%
Nov 30, 2024 Lazard Asset Management Llc 19,684 0.02%
Oct 31, 2024 Lazard Asset Management Llc 19,684 0.02%
Sep 30, 2024 Lazard Asset Management Llc 74,922 0.08%
Sep 30, 2024 Lazard Asset Management Llc 19,684 0.02%
Aug 31, 2024 Lazard Asset Management Llc 15,819 0.02%
Jul 31, 2024 Lazard Asset Management Llc 15,819 0.02%
Jun 30, 2024 Lazard Asset Management Llc 61,433 0.06%
Jun 30, 2024 Lazard Asset Management Llc 17,130 0.02%
May 31, 2024 Lazard Asset Management Llc 15,659 0.02%
Apr 30, 2024 Lazard Asset Management Llc 15,330 0.02%
Mar 31, 2024 Lazard Asset Management Llc 55,329 0.05%
Mar 31, 2024 Lazard Asset Management Llc 15,330 0.02%
Feb 29, 2024 Lazard Asset Management Llc 11,122 0.01%
Jan 31, 2024 Lazard Asset Management Llc 11,122 0.01%
Dec 31, 2023 Lazard Asset Management Llc 46,445 0.05%
Dec 31, 2023 Lazard Asset Management Llc 1,478 0.00%
Nov 30, 2023 Lazard Asset Management Llc 1,478 0.00%
Oct 31, 2023 Lazard Asset Management Llc 776 0.00%
Sep 30, 2023 Lazard Asset Management Llc 27,253 0.03%
Sep 30, 2023 Lazard Asset Management Llc 658 0.00%
Aug 31, 2023 Lazard Asset Management Llc 1,815 0.00%
Jul 31, 2023 Lazard Asset Management Llc 1,815 0.00%
Jun 30, 2023 Lazard Asset Management Llc 1,860 0.00%
Jun 30, 2023 Lazard Asset Management Llc 21,678 0.02%
May 31, 2023 Lazard Asset Management Llc 21,687 0.02%
Mar 31, 2023 Lazard Asset Management Llc 44,987 0.05%
Dec 31, 2022 Lazard Asset Management Llc 4,235 0.00%

View all ownership details of Neurocrine Biosciences, Inc.